LeadBio Announces Tens of Millions RMB Pre-A Financing from Boxing Capital to Advance Bioengineered Vascular Grafts

Investment Circle (ID: pedaily2012) reported on April 24 that LEADBIO, short for LEADBIO Biotechnology (Hangzhou) Co., Ltd., has secured a tens-of-millions-yuan Pre-A financing round invested by Boxing Capital, just months after closing its multi-million-yuan angel round led by Taiyu Investment. LEADBIO stated, “The proceeds from this financing round will be used for the preclinical research of our bio-based artificial blood vessels and the development of new products.”

According to reports, LEADBIO was founded in 2019 and is located in the Medicine Port of Hangzhou Qiantang New Area. The company is dedicated to the research and development of tissue-engineered regenerative material products that can replace and repair human tissues and organs, with the aspiration of becoming a globally leading platform enterprise for the research, development, and manufacturing of artificial organs and tissue repair products.

According to the introduction,LEADBIO’s first artificial blood vessel product will be applied in arteriovenous graft (AVG) surgery for hemodialysis patients, and in the future, this artificial blood vessel is expected to be extended to the treatment of other vascular diseases.

LEADBIO's Biological HumanThe artificial vascular graft is currently the only medical product worldwide that combines polymer materials with decellularized matrix. The polymer materials provide the graft with excellent mechanical properties, while the decellularized matrix enhances biocompatibility and makes endothelialization of the artificial vessel possible. This technology holds potential for future applications in areas such as artificial esophagus development, tissue repair, and reconstructive surgery.